Beckwith-Wiedemann syndrome (BWS) is a genetic overgrowth and cancer predisposition syndrome, associated with both benign and malignant adrenal findings. Literature review and an institutional case series elucidate the wide spectrum of adrenal findings in BWS patients. The altered expression of the 11p15 region is likely related to adrenal gland hyperplasia and growth dysregulation. Given the absence of guidelines for managing adrenal findings in BWS, we propose a systematic approach to adrenal findings in BWS patients, to allow for maximum detection of potentially malignant pathology without posing additional risk to patients.
INTRODUCTION
Beckwith-Wiedemann syndrome (BWS, OMIM #130650) is a genetic overgrowth and cancer predisposition syndrome characterized by hemihypertrophy, macroglossia, macrosomia, organomegaly, hyperinsulinism, omphalocele/umbilical hernia, and distinct facial features. 1 Patients with BWS are also at risk for embyronal tumors such as Wilms tumor, hepatoblastoma, and neuroblastoma in the first 8 years of life. [1] [2] [3] [4] [5] BWS is caused by genetic or epigenetic changes on chromosome 11p15, with either specific gene mutations or changes in Abbreviations: ACTH, adrenocorticotropic hormone; AFP, alpha-fetoprotein; BWS, Beckwith-Wiedemann syndrome; CDKN1C, cyclin-dependent kinase inhibitor 1C; COG, Children's Oncology Group; DHEAS, dehydroepiandrosterone sulfate; IC1, imprinting center 1; IC2, imprinting center 2; IGF2, insulin-like growth factor 2; LOH, loss of heterozygosity; IHH, isolated hemihypertrophy; MIBG, meta-iodobenzylguanidine; pUPD11, paternal uniparental disomy 11 DNA methylation in imprinting centers, known as imprinting center 1, H19/IGF2:IG-DMR (IC1), and imprinting center 2, KCNQ1OT1:TSS-DMR 2 (IC2), leading to a dysregulation in genes affecting growth. 1 BWS is more generally classified as the 11p overgrowth spectrum, which includes the spectrum of patients from classic BWS to those with isolated hemihypertrophy (IHH). 6, 7 For the purposes of these recommendations, we will henceforward refer only to BWS, but would recommend these screening guidelines for any patient within the 11p overgrowth spectrum, including BWS and IHH.
The overall risk of intra-abdominal tumor development in BWS is somewhere between 5 and 10%. [2] [3] [4] [5] and nonmalignant adrenal masses are reported. 4 Given this frequency, a consistent approach for evaluating adrenal masses in BWS is warranted.
Recommendations for following an incidentally noted adrenal mass have been developed for otherwise normal patients, 8 but there are no recommendations for adrenal evaluation in patients with BWS. These patients have an increased risk of malignancy, and this must be considered and weighed against the risk of further diagnostic evaluation with biopsy or resection. The objective of this study is to review the adrenal findings in a large number of BWS patients evaluated at a BWS referral center, propose a potential underlying mechanism for the higher incidence of adrenal findings, and delineate steps for the evaluation of an adrenal mass detected during surveillance screening.
METHODS
We conducted a literature review most recently updated in September 2016 via PubMed and the Cochrane Library for case reports and series involving patients with BWS and adrenal findings. These were compiled and analyzed for inclusion based on their relevance to the subject matter included in this review.
Our institutional database of patients with BWS (Children's Hospital of Philadelphia, IRB #13-010658) was reviewed for patients with adrenal findings. Evaluation and clinical decisions for these patients were made in accordance with currently available literature regarding adrenal mass management in pediatric patients. Age subdivision and size classification were based on the Children's Oncology Group (COG)
guidelines for the management of infants with adrenal masses concerning for neuroblastoma. 9 Additionally, a comprehensive literature review was conducted to review both any available guidelines for management of incidentally noted adrenal masses in adults, as well as prior studies of expectant management of infantile neuroblastoma detected by mass screening in Japan. 8, 10 Guidelines were established using this available literature and institutional experience with BWS.
RESULTS
Literature review reveals a significant variation in the type of adrenal mass detected in BWS ( 
DISCUSSION
The literature review and our institutional findings demonstrate significant diversity in adrenal findings in BWS patients. As these patients are predisposed to multiple cancer types, including adrenocortical carcinoma, it is important to appropriately screen and treat these patients when masses are uncovered on routine screening. In the following sections, we propose a system for evaluation of patients with BWS and adrenal findings based on the increased risk of malignancy in these patients.
Underlying physiology of adrenal findings in BWS
There are several genetic changes that lead to the BWS pheno- imprinting centers, leading to aberrant 11p15 methylation. 38 These alterations in expression of IGF2 and CDKN1C can lead to deviations in fetal adrenal development.
Development of the fetal adrenal gland is a complex and highly regulated process, and IGF2 is a major modulator in fetal adrenal growth and steroidogenesis. 39, 40 In two large sequencing projects evaluating pediatric patients with adrenocortical tumors, IGF2 was overexpressed (with 11p loss of heterozygosity) in the majority of tumors. 41, 42 IGF2 overexpression promotes adrenocortical carcinoma, but its expression alone is not sufficient for adrenal carcinogenesis. 43 Thus, an increase in IGF2 expression seen in BWS could similarly affect fetal adrenal development.
Alterations in CDKN1C expression have also been tied to changes in adrenal growth and development. In a Cdkn1c knockdown mouse model, adrenal cell hyperplasia was noted, most notably in the adrenal cortex. 44 Alternatively, patients with gain of function CDKN1C mutations are phenotypically growth restricted, and in particular have adrenal hypoplasia. 38 Therefore, IGF2 overexpression and CDKN1C downregulation in patients with BWS is a plausible explanation for adrenal cortex hypertrophy, as well as predisposition to adrenocortical malignancy.
In our case series, epigenetic changes leading to dysregulated IGF2 expression was present in 78% (7/9) of the patients with adrenal findings, and the other two patients had IC2 loss of methylation and decreased CDKN1C expression (Supplementary Table S1 ). Based on previous research showing that these aberrations lead to abnormal fetal adrenal development and potentially predispose to malignancy, this is a plausible explanation for the increased frequency of adrenal findings in BWS. The patients in our institutional case series had a spectrum of adrenal change, from adrenal hemorrhage or adrenal cytomegaly to malignant tumors such as neuroblastoma. Further investigation is necessary for a better understanding of the genetic mechanism leading to adrenal masses in BWS.
Recent studies of patients with BWS have shown that the epigenotype influences the phenotypic risk of cancer; yet to date, no molecular subgroup is predictive of risk of adrenocortical tumors. 3, 7, 45 It is possible that with further understanding of mechanism, patients at higher risk of adrenal masses may be identified based on their epigenotype.
In the absence of an epigenetic stratification, we propose a method to identify and evaluate patients with BWS at higher risk of adrenal malignancy.
Clinical evaluation of adrenal masses in BWS
As shown in a review of available literature and in our own institutional case series, adrenal findings are common in BWS patients and require further evaluation given the increased adrenal tumor risk in these patients, as compared with patients without BWS. Our recommended general approach to adrenal findings discovered on routine surveillance screening in patients with BWS is shown in Figure 1 . Our goal is to risk stratify patients based on age and clinical features to prevent adverse outcomes without leading to unnecessary imaging or invasive procedures in these patients.
We first evaluate patients for the presence of high-risk features, as defined below, and the nature of the mass (cystic vs. solid). Increasing the size of an adrenal mass during the observation period should also raise concern, with the patient requiring closer follow-up evaluations and more regularly scheduled surveillance imaging. A 50% increase in size was established by COG in monitoring adrenal masses in patients less than 6 months of age, and has been effective in riskstratifying patients with high-risk lesions in this population; 5 mm has been used in other observational studies. 9, 48 If the size of the mass increases by 50% or more during the observation period (2 years after finding or until it is no longer present), the mass should undergo complete resection. If the mass increases by less than 50%, the patient should have imaging at 3-6-week intervals until the mass size stabilizes (or until the mass is resected).
Cystic masses
For patients with cystic masses without high-risk features, regardless of age, observation alone with ultrasound imaging every 3 months is adequate, as the majority of these cysts represent an adrenal cyst or hemorrhage. For a mixed cystic/solid mass, we recommend evaluation based on patient age.
Age
Adrenal masses in patients less than 6 months of age are less likely to be malignant or require surgical intervention. 46 Several studies have shown that systematic and close observation in these patients, with careful monitoring parameters, is a safe approach. 46, 47 Observation of patients with adrenal masses less than 6 months of age has been shown prospectively by COG to capture all high-risk lesions with 100% survival, and this is now the standard of care. 9 We have adopted the COG proposed criteria for expectant observation in adrenal masses less than 6 months, with some modifications given the increased risk of tumor in patients with BWS. 4 The majority of these masses are a localized neuroblastoma with favorable outcome, and the remainder are more likely to be benign. 46 This critical approach allows sparing of surgery in these patients, as surgery poses a higher risk to these patients than localized neuroblastoma. 9
Less than 6 months
Based on the COG criteria, in a patient less than 6 months of age with an adrenal mass, observation alone is acceptable if the mass meets certain criteria 46, 47 : for a small, solid adrenal mass (≤16 ml volume/3.1 cm diameter) or mixed solid and cystic adrenal mass less than or equal to 65 ml (if >25% cystic), a first step evaluation includes urine catecholamine metabolites, whole body imaging, and a radiolabeled metaiodobenzylguanidine (MIBG) scan to evaluate for neuroblastoma and A tumor suspected to be an adrenocortical carcinoma should be fully resected without biopsy. Abnormal adrenocortical hormone levels,
should they be present, will provide a biomarker after surgical resection. Additionally, for patients with abnormal laboratories, involvement of endocrinology may be warranted for their pre-and postoperative management.
If the proposed imaging and laboratory studies are reassuring, these patients can be followed with an ultrasound evaluation every 6 weeks for up to 2 years after the initial mass is seen, then transitioned to every 3 months until 8 years of age. The end of surveillance can also be modified if a patient has high-risk features, or a tumor that is at high risk of late recurrence, such as pheochromocytoma. For patients with highrisk features as previously defined, or patients with a mass that is larger than the size cutoff (16 ml or 3.1 cm diameter, or 65 ml if >25% cystic),
should be referred to the pathway for patients 6 months or older.
At and over 6 months
In patients 6 months of age or older, solid adrenal masses are more likely to be malignant, and thus these patients require a more thorough evaluation. Additionally, in the case of a BWS patient with an adrenal mass, the increased risk of adrenocortical carcinoma should be considered; the risk of adrenocortical tumor is higher in these patients than in the general population of patients with an adrenal mass, and a biopsy of an adrenocortical carcinoma without proper preparation will increase risk to the patient.
In any patient with BWS with an adrenal mass, either solid or mixed solid/cystic, the first step should be further imaging evaluation with a magnetic resonance imaging to better delineate the mass and to prepare for a possible surgical approach. After initial imag- 
CONCLUSIONS
Adrenal masses are more frequent in patients with BWS than in the general population. Based on our institutional experience with this patient population, we propose an evaluation pathway for these patients in addition to BWS protocols. The proposed evaluation pathway balances the risks of unnecessary testing and procedures, while still ensuring that high-risk adrenal masses are diagnosed and treated appropriately. Additionally, these guidelines more broadly outline the available recommendations for evaluating adrenal masses in the pediatric patient; while they account for the increased risk of adrenal malignancy in the BWS population, a similar schema could be considered for any child with an adrenal mass. 
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